Agriculture
Inactivated Vaccine for Swine Mycoplasma Pneumonia - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
- Nov 01, 24
- ID: 618550
- Pages: 127
- Figures: 249
- Views: 1
Inactivated vaccines for Swine Mycoplasma pneumonia are also available. They are made by using inactivated or killed strains of the bacteria to stimulate an immune response in pigs without causing disease.
The global market for Inactivated Vaccine for Swine Mycoplasma Pneumonia was estimated to be worth US$ 342 million in 2023 and is forecast to a readjusted size of US$ 587.8 million by 2030 with a CAGR of 7.4% during the forecast period 2024-2030
North American market for Inactivated Vaccine for Swine Mycoplasma Pneumonia was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Inactivated Vaccine for Swine Mycoplasma Pneumonia was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Inactivated Vaccine for Swine Mycoplasma Pneumonia was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Inactivated Vaccine for Swine Mycoplasma Pneumonia include Zoetis, Boehringer Ingelheim, Jinhe Biotechnology, Merck, HIPRA, Ceva Santé Animale, Harbin Pharmaceutical Group, Pulike Biotech and Qilu Animal Health Products, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Inactivated Vaccine for Swine Mycoplasma Pneumonia, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Inactivated Vaccine for Swine Mycoplasma Pneumonia by region & country, by Type, and by Application.
The Inactivated Vaccine for Swine Mycoplasma Pneumonia market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Inactivated Vaccine for Swine Mycoplasma Pneumonia.
Market Segmentation
By Company
Zoetis
Boehringer Ingelheim
Jinhe Biotechnology
Merck
HIPRA
Ceva Santé Animale
Harbin Pharmaceutical Group
Pulike Biotech
Qilu Animal Health Products
Wuhan Keqian Biology
Segment by Type:
Single Vaccine
Dual Vaccine
Segment by Application
Piglets
Adult Pigs
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Inactivated Vaccine for Swine Mycoplasma Pneumonia manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Inactivated Vaccine for Swine Mycoplasma Pneumonia in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Inactivated Vaccine for Swine Mycoplasma Pneumonia in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
The global market for Inactivated Vaccine for Swine Mycoplasma Pneumonia was estimated to be worth US$ 342 million in 2023 and is forecast to a readjusted size of US$ 587.8 million by 2030 with a CAGR of 7.4% during the forecast period 2024-2030
North American market for Inactivated Vaccine for Swine Mycoplasma Pneumonia was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Inactivated Vaccine for Swine Mycoplasma Pneumonia was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Inactivated Vaccine for Swine Mycoplasma Pneumonia was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Inactivated Vaccine for Swine Mycoplasma Pneumonia include Zoetis, Boehringer Ingelheim, Jinhe Biotechnology, Merck, HIPRA, Ceva Santé Animale, Harbin Pharmaceutical Group, Pulike Biotech and Qilu Animal Health Products, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Inactivated Vaccine for Swine Mycoplasma Pneumonia, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Inactivated Vaccine for Swine Mycoplasma Pneumonia by region & country, by Type, and by Application.
The Inactivated Vaccine for Swine Mycoplasma Pneumonia market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Inactivated Vaccine for Swine Mycoplasma Pneumonia.
Market Segmentation
By Company
Zoetis
Boehringer Ingelheim
Jinhe Biotechnology
Merck
HIPRA
Ceva Santé Animale
Harbin Pharmaceutical Group
Pulike Biotech
Qilu Animal Health Products
Wuhan Keqian Biology
Segment by Type:
Single Vaccine
Dual Vaccine
Segment by Application
Piglets
Adult Pigs
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Inactivated Vaccine for Swine Mycoplasma Pneumonia manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Inactivated Vaccine for Swine Mycoplasma Pneumonia in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Inactivated Vaccine for Swine Mycoplasma Pneumonia in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
1 Market Overview
1.1 Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Introduction
1.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast
1.2.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value (2019-2030)
1.2.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume (2019-2030)
1.2.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Price (2019-2030)
1.3 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Trends & Drivers
1.3.1 Inactivated Vaccine for Swine Mycoplasma Pneumonia Industry Trends
1.3.2 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Drivers & Opportunity
1.3.3 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Challenges
1.3.4 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Players Revenue Ranking (2023)
2.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue by Company (2019-2024)
2.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Players Sales Volume Ranking (2023)
2.4 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Company Players (2019-2024)
2.5 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Company (2019-2024)
2.6 Key Manufacturers Inactivated Vaccine for Swine Mycoplasma Pneumonia Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Inactivated Vaccine for Swine Mycoplasma Pneumonia
2.9 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Competitive Analysis
2.9.1 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Inactivated Vaccine for Swine Mycoplasma Pneumonia as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Single Vaccine
3.1.2 Dual Vaccine
3.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Type
3.2.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, by Type (2019-2030)
3.2.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, by Type (%) (2019-2030)
3.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Type
3.3.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume, by Type (2019-2030)
3.3.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume, by Type (%) (2019-2030)
3.4 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Piglets
4.1.2 Adult Pigs
4.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Application
4.2.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, by Application (2019-2030)
4.2.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, by Application (%) (2019-2030)
4.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Application
4.3.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume, by Application (2019-2030)
4.3.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume, by Application (%) (2019-2030)
4.4 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Region
5.1.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Region (2019-2024)
5.1.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Region (2025-2030)
5.1.4 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Region (%), (2019-2030)
5.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Region
5.2.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Region (2019-2024)
5.2.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Region (2025-2030)
5.2.4 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Region (%), (2019-2030)
5.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, 2019-2030
5.4.2 North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, 2019-2030
5.5.2 Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, 2019-2030
5.6.2 Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, 2019-2030
5.7.2 South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, 2019-2030
5.8.2 Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value
6.2.1 Key Countries/Regions Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, 2019-2030
6.2.2 Key Countries/Regions Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, 2019-2030
6.3.2 United States Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, 2019-2030
6.4.2 Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, 2019-2030
6.5.2 China Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Type (%), 2023 VS 2030
6.5.3 China Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, 2019-2030
6.6.2 Japan Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, 2019-2030
6.7.2 South Korea Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, 2019-2030
6.8.2 Southeast Asia Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, 2019-2030
6.9.2 India Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Type (%), 2023 VS 2030
6.9.3 India Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Zoetis
7.1.1 Zoetis Company Information
7.1.2 Zoetis Introduction and Business Overview
7.1.3 Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
7.1.5 Zoetis Recent Development
7.2 Boehringer Ingelheim
7.2.1 Boehringer Ingelheim Company Information
7.2.2 Boehringer Ingelheim Introduction and Business Overview
7.2.3 Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
7.2.5 Boehringer Ingelheim Recent Development
7.3 Jinhe Biotechnology
7.3.1 Jinhe Biotechnology Company Information
7.3.2 Jinhe Biotechnology Introduction and Business Overview
7.3.3 Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
7.3.5 Jinhe Biotechnology Recent Development
7.4 Merck
7.4.1 Merck Company Information
7.4.2 Merck Introduction and Business Overview
7.4.3 Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
7.4.5 Merck Recent Development
7.5 HIPRA
7.5.1 HIPRA Company Information
7.5.2 HIPRA Introduction and Business Overview
7.5.3 HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales, Revenue and Gross Margin (2019-2024)
7.5.4 HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
7.5.5 HIPRA Recent Development
7.6 Ceva Santé Animale
7.6.1 Ceva Santé Animale Company Information
7.6.2 Ceva Santé Animale Introduction and Business Overview
7.6.3 Ceva Santé Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Ceva Santé Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
7.6.5 Ceva Santé Animale Recent Development
7.7 Harbin Pharmaceutical Group
7.7.1 Harbin Pharmaceutical Group Company Information
7.7.2 Harbin Pharmaceutical Group Introduction and Business Overview
7.7.3 Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
7.7.5 Harbin Pharmaceutical Group Recent Development
7.8 Pulike Biotech
7.8.1 Pulike Biotech Company Information
7.8.2 Pulike Biotech Introduction and Business Overview
7.8.3 Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
7.8.5 Pulike Biotech Recent Development
7.9 Qilu Animal Health Products
7.9.1 Qilu Animal Health Products Company Information
7.9.2 Qilu Animal Health Products Introduction and Business Overview
7.9.3 Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
7.9.5 Qilu Animal Health Products Recent Development
7.10 Wuhan Keqian Biology
7.10.1 Wuhan Keqian Biology Company Information
7.10.2 Wuhan Keqian Biology Introduction and Business Overview
7.10.3 Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
7.10.5 Wuhan Keqian Biology Recent Development
8 Industry Chain Analysis
8.1 Inactivated Vaccine for Swine Mycoplasma Pneumonia Industrial Chain
8.2 Inactivated Vaccine for Swine Mycoplasma Pneumonia Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Model
8.5.2 Sales Channel
8.5.3 Inactivated Vaccine for Swine Mycoplasma Pneumonia Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
1.1 Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Introduction
1.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Size Forecast
1.2.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value (2019-2030)
1.2.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume (2019-2030)
1.2.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Price (2019-2030)
1.3 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Trends & Drivers
1.3.1 Inactivated Vaccine for Swine Mycoplasma Pneumonia Industry Trends
1.3.2 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Drivers & Opportunity
1.3.3 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Challenges
1.3.4 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Players Revenue Ranking (2023)
2.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue by Company (2019-2024)
2.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Players Sales Volume Ranking (2023)
2.4 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Company Players (2019-2024)
2.5 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Company (2019-2024)
2.6 Key Manufacturers Inactivated Vaccine for Swine Mycoplasma Pneumonia Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Inactivated Vaccine for Swine Mycoplasma Pneumonia
2.9 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Competitive Analysis
2.9.1 Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Inactivated Vaccine for Swine Mycoplasma Pneumonia as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Single Vaccine
3.1.2 Dual Vaccine
3.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Type
3.2.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, by Type (2019-2030)
3.2.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, by Type (%) (2019-2030)
3.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Type
3.3.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume, by Type (2019-2030)
3.3.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume, by Type (%) (2019-2030)
3.4 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Piglets
4.1.2 Adult Pigs
4.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Application
4.2.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, by Application (2019-2030)
4.2.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, by Application (%) (2019-2030)
4.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Application
4.3.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume, by Application (2019-2030)
4.3.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume, by Application (%) (2019-2030)
4.4 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Region
5.1.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Region (2019-2024)
5.1.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Region (2025-2030)
5.1.4 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Region (%), (2019-2030)
5.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Region
5.2.1 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Region (2019-2024)
5.2.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Region (2025-2030)
5.2.4 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Region (%), (2019-2030)
5.3 Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, 2019-2030
5.4.2 North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, 2019-2030
5.5.2 Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, 2019-2030
5.6.2 Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, 2019-2030
5.7.2 South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, 2019-2030
5.8.2 Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value
6.2.1 Key Countries/Regions Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, 2019-2030
6.2.2 Key Countries/Regions Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, 2019-2030
6.3.2 United States Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, 2019-2030
6.4.2 Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, 2019-2030
6.5.2 China Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Type (%), 2023 VS 2030
6.5.3 China Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, 2019-2030
6.6.2 Japan Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, 2019-2030
6.7.2 South Korea Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, 2019-2030
6.8.2 Southeast Asia Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, 2019-2030
6.9.2 India Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Type (%), 2023 VS 2030
6.9.3 India Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Zoetis
7.1.1 Zoetis Company Information
7.1.2 Zoetis Introduction and Business Overview
7.1.3 Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
7.1.5 Zoetis Recent Development
7.2 Boehringer Ingelheim
7.2.1 Boehringer Ingelheim Company Information
7.2.2 Boehringer Ingelheim Introduction and Business Overview
7.2.3 Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
7.2.5 Boehringer Ingelheim Recent Development
7.3 Jinhe Biotechnology
7.3.1 Jinhe Biotechnology Company Information
7.3.2 Jinhe Biotechnology Introduction and Business Overview
7.3.3 Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
7.3.5 Jinhe Biotechnology Recent Development
7.4 Merck
7.4.1 Merck Company Information
7.4.2 Merck Introduction and Business Overview
7.4.3 Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
7.4.5 Merck Recent Development
7.5 HIPRA
7.5.1 HIPRA Company Information
7.5.2 HIPRA Introduction and Business Overview
7.5.3 HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales, Revenue and Gross Margin (2019-2024)
7.5.4 HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
7.5.5 HIPRA Recent Development
7.6 Ceva Santé Animale
7.6.1 Ceva Santé Animale Company Information
7.6.2 Ceva Santé Animale Introduction and Business Overview
7.6.3 Ceva Santé Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Ceva Santé Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
7.6.5 Ceva Santé Animale Recent Development
7.7 Harbin Pharmaceutical Group
7.7.1 Harbin Pharmaceutical Group Company Information
7.7.2 Harbin Pharmaceutical Group Introduction and Business Overview
7.7.3 Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
7.7.5 Harbin Pharmaceutical Group Recent Development
7.8 Pulike Biotech
7.8.1 Pulike Biotech Company Information
7.8.2 Pulike Biotech Introduction and Business Overview
7.8.3 Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
7.8.5 Pulike Biotech Recent Development
7.9 Qilu Animal Health Products
7.9.1 Qilu Animal Health Products Company Information
7.9.2 Qilu Animal Health Products Introduction and Business Overview
7.9.3 Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
7.9.5 Qilu Animal Health Products Recent Development
7.10 Wuhan Keqian Biology
7.10.1 Wuhan Keqian Biology Company Information
7.10.2 Wuhan Keqian Biology Introduction and Business Overview
7.10.3 Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
7.10.5 Wuhan Keqian Biology Recent Development
8 Industry Chain Analysis
8.1 Inactivated Vaccine for Swine Mycoplasma Pneumonia Industrial Chain
8.2 Inactivated Vaccine for Swine Mycoplasma Pneumonia Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Model
8.5.2 Sales Channel
8.5.3 Inactivated Vaccine for Swine Mycoplasma Pneumonia Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
List of Tables
Table 1. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Trends
Table 2. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Drivers & Opportunity
Table 3. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Challenges
Table 4. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Restraints
Table 5. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue Market Share by Company (2019-2024)
Table 7. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Company (2019-2024) & (K Units)
Table 8. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume Market Share by Company (2019-2024)
Table 9. Global Market Inactivated Vaccine for Swine Mycoplasma Pneumonia Price by Company (2019-2024) & (US$/Unit)
Table 10. Key Manufacturers Inactivated Vaccine for Swine Mycoplasma Pneumonia Manufacturing Base Distribution and Headquarters
Table 11. Key Manufacturers Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Inactivated Vaccine for Swine Mycoplasma Pneumonia
Table 13. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Inactivated Vaccine for Swine Mycoplasma Pneumonia as of 2023)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 17. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Type (2019-2024) & (US$ Million)
Table 18. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Type (2025-2030) & (US$ Million)
Table 19. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share in Value by Type (2019-2024) & (%)
Table 20. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share in Value by Type (2025-2030) & (%)
Table 21. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
Table 22. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Type (2019-2024) & (K Units)
Table 23. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Type (2025-2030) & (K Units)
Table 24. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share in Volume by Type (2019-2024) & (%)
Table 25. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share in Volume by Type (2025-2030) & (%)
Table 26. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price by Type (2019-2024) & (US$/Unit)
Table 27. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price by Type (2025-2030) & (US$/Unit)
Table 28. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Application (2019-2024) & (US$ Million)
Table 30. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Application (2025-2030) & (US$ Million)
Table 31. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share in Value by Application (2019-2024) & (%)
Table 32. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share in Value by Application (2025-2030) & (%)
Table 33. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
Table 34. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Application (2019-2024) & (K Units)
Table 35. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Application (2025-2030) & (K Units)
Table 36. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share in Volume by Application (2019-2024) & (%)
Table 37. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share in Volume by Application (2025-2030) & (%)
Table 38. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price by Application (2019-2024) & (US$/Unit)
Table 39. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price by Application (2025-2030) & (US$/Unit)
Table 40. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Region (2019-2024) & (US$ Million)
Table 42. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Region (2025-2030) & (US$ Million)
Table 43. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Region (2019-2024) & (%)
Table 44. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Region (2025-2030) & (%)
Table 45. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
Table 46. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Region (2019-2024) & (K Units)
Table 47. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Region (2025-2030) & (K Units)
Table 48. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Region (2019-2024) & (%)
Table 49. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Region (2025-2030) & (%)
Table 50. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Region (2019-2024) & (US$/Unit)
Table 51. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Region (2025-2030) & (US$/Unit)
Table 52. Key Countries/Regions Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 53. Key Countries/Regions Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, (2019-2024) & (US$ Million)
Table 54. Key Countries/Regions Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, (2025-2030) & (US$ Million)
Table 55. Key Countries/Regions Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume, (2019-2024) & (K Units)
Table 56. Key Countries/Regions Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume, (2025-2030) & (K Units)
Table 57. Zoetis Company Information
Table 58. Zoetis Introduction and Business Overview
Table 59. Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 60. Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
Table 61. Zoetis Recent Development
Table 62. Boehringer Ingelheim Company Information
Table 63. Boehringer Ingelheim Introduction and Business Overview
Table 64. Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 65. Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
Table 66. Boehringer Ingelheim Recent Development
Table 67. Jinhe Biotechnology Company Information
Table 68. Jinhe Biotechnology Introduction and Business Overview
Table 69. Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 70. Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
Table 71. Jinhe Biotechnology Recent Development
Table 72. Merck Company Information
Table 73. Merck Introduction and Business Overview
Table 74. Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 75. Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
Table 76. Merck Recent Development
Table 77. HIPRA Company Information
Table 78. HIPRA Introduction and Business Overview
Table 79. HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 80. HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
Table 81. HIPRA Recent Development
Table 82. Ceva Santé Animale Company Information
Table 83. Ceva Santé Animale Introduction and Business Overview
Table 84. Ceva Santé Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 85. Ceva Santé Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
Table 86. Ceva Santé Animale Recent Development
Table 87. Harbin Pharmaceutical Group Company Information
Table 88. Harbin Pharmaceutical Group Introduction and Business Overview
Table 89. Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 90. Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
Table 91. Harbin Pharmaceutical Group Recent Development
Table 92. Pulike Biotech Company Information
Table 93. Pulike Biotech Introduction and Business Overview
Table 94. Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 95. Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
Table 96. Pulike Biotech Recent Development
Table 97. Qilu Animal Health Products Company Information
Table 98. Qilu Animal Health Products Introduction and Business Overview
Table 99. Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 100. Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
Table 101. Qilu Animal Health Products Recent Development
Table 102. Wuhan Keqian Biology Company Information
Table 103. Wuhan Keqian Biology Introduction and Business Overview
Table 104. Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 105. Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
Table 106. Wuhan Keqian Biology Recent Development
Table 107. Key Raw Materials Lists
Table 108. Raw Materials Key Suppliers Lists
Table 109. Inactivated Vaccine for Swine Mycoplasma Pneumonia Downstream Customers
Table 110. Inactivated Vaccine for Swine Mycoplasma Pneumonia Distributors List
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
List of Figures
Figure 1. Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Picture
Figure 2. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value (2019-2030) & (US$ Million)
Figure 4. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume (2019-2030) & (K Units)
Figure 5. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Price (2019-2030) & (US$/Unit)
Figure 6. Inactivated Vaccine for Swine Mycoplasma Pneumonia Report Years Considered
Figure 7. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Players Revenue Ranking (2023) & (US$ Million)
Figure 8. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Players Sales Volume Ranking (2023) & (K Units)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue in 2023
Figure 10. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 11. Single Vaccine Picture
Figure 12. Dual Vaccine Picture
Figure 13. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 14. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value Market Share by Type, 2023 & 2030
Figure 15. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
Figure 16. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume Market Share by Type, 2023 & 2030
Figure 17. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price by Type (2019-2030) & (US$/Unit)
Figure 18. Product Picture of Piglets
Figure 19. Product Picture of Adult Pigs
Figure 20. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 21. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value Market Share by Application, 2023 & 2030
Figure 22. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
Figure 23. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume Market Share by Application, 2023 & 2030
Figure 24. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price by Application (2019-2030) & (US$/Unit)
Figure 25. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value (2019-2030) & (US$ Million)
Figure 26. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Country (%), 2023 VS 2030
Figure 27. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value (2019-2030) & (US$ Million)
Figure 28. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Country (%), 2023 VS 2030
Figure 29. Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value (2019-2030) & (US$ Million)
Figure 30. Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Country (%), 2023 VS 2030
Figure 31. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value (2019-2030) & (US$ Million)
Figure 32. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Country (%), 2023 VS 2030
Figure 33. Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value (2019-2030) & (US$ Million)
Figure 34. Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Country (%), 2023 VS 2030
Figure 35. Key Countries/Regions Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value (%), (2019-2030)
Figure 36. Key Countries/Regions Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume (%), (2019-2030)
Figure 37. United States Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, (2019-2030) & (US$ Million)
Figure 38. United States Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Type (%), 2023 VS 2030
Figure 39. United States Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Application (%), 2023 VS 2030
Figure 40. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, (2019-2030) & (US$ Million)
Figure 41. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Type (%), 2023 VS 2030
Figure 42. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Application (%), 2023 VS 2030
Figure 43. China Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, (2019-2030) & (US$ Million)
Figure 44. China Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Type (%), 2023 VS 2030
Figure 45. China Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Application (%), 2023 VS 2030
Figure 46. Japan Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, (2019-2030) & (US$ Million)
Figure 47. Japan Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Type (%), 2023 VS 2030
Figure 48. Japan Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Application (%), 2023 VS 2030
Figure 49. South Korea Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, (2019-2030) & (US$ Million)
Figure 50. South Korea Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Type (%), 2023 VS 2030
Figure 51. South Korea Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Application (%), 2023 VS 2030
Figure 52. Southeast Asia Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, (2019-2030) & (US$ Million)
Figure 53. Southeast Asia Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Type (%), 2023 VS 2030
Figure 54. Southeast Asia Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Application (%), 2023 VS 2030
Figure 55. India Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, (2019-2030) & (US$ Million)
Figure 56. India Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Type (%), 2023 VS 2030
Figure 57. India Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Application (%), 2023 VS 2030
Figure 58. Inactivated Vaccine for Swine Mycoplasma Pneumonia Industrial Chain
Figure 59. Inactivated Vaccine for Swine Mycoplasma Pneumonia Manufacturing Cost Structure
Figure 60. Channels of Distribution (Direct Sales, and Distribution)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Table 1. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Trends
Table 2. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Drivers & Opportunity
Table 3. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Challenges
Table 4. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Restraints
Table 5. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue Market Share by Company (2019-2024)
Table 7. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Company (2019-2024) & (K Units)
Table 8. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume Market Share by Company (2019-2024)
Table 9. Global Market Inactivated Vaccine for Swine Mycoplasma Pneumonia Price by Company (2019-2024) & (US$/Unit)
Table 10. Key Manufacturers Inactivated Vaccine for Swine Mycoplasma Pneumonia Manufacturing Base Distribution and Headquarters
Table 11. Key Manufacturers Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Inactivated Vaccine for Swine Mycoplasma Pneumonia
Table 13. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Inactivated Vaccine for Swine Mycoplasma Pneumonia as of 2023)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 17. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Type (2019-2024) & (US$ Million)
Table 18. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Type (2025-2030) & (US$ Million)
Table 19. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share in Value by Type (2019-2024) & (%)
Table 20. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share in Value by Type (2025-2030) & (%)
Table 21. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
Table 22. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Type (2019-2024) & (K Units)
Table 23. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Type (2025-2030) & (K Units)
Table 24. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share in Volume by Type (2019-2024) & (%)
Table 25. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share in Volume by Type (2025-2030) & (%)
Table 26. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price by Type (2019-2024) & (US$/Unit)
Table 27. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price by Type (2025-2030) & (US$/Unit)
Table 28. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Application (2019-2024) & (US$ Million)
Table 30. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Application (2025-2030) & (US$ Million)
Table 31. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share in Value by Application (2019-2024) & (%)
Table 32. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share in Value by Application (2025-2030) & (%)
Table 33. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
Table 34. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Application (2019-2024) & (K Units)
Table 35. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Application (2025-2030) & (K Units)
Table 36. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share in Volume by Application (2019-2024) & (%)
Table 37. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Market Share in Volume by Application (2025-2030) & (%)
Table 38. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price by Application (2019-2024) & (US$/Unit)
Table 39. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price by Application (2025-2030) & (US$/Unit)
Table 40. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Region (2019-2024) & (US$ Million)
Table 42. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Region (2025-2030) & (US$ Million)
Table 43. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Region (2019-2024) & (%)
Table 44. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Region (2025-2030) & (%)
Table 45. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
Table 46. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Region (2019-2024) & (K Units)
Table 47. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Region (2025-2030) & (K Units)
Table 48. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Region (2019-2024) & (%)
Table 49. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Region (2025-2030) & (%)
Table 50. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Region (2019-2024) & (US$/Unit)
Table 51. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Average Price by Region (2025-2030) & (US$/Unit)
Table 52. Key Countries/Regions Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 53. Key Countries/Regions Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, (2019-2024) & (US$ Million)
Table 54. Key Countries/Regions Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, (2025-2030) & (US$ Million)
Table 55. Key Countries/Regions Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume, (2019-2024) & (K Units)
Table 56. Key Countries/Regions Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume, (2025-2030) & (K Units)
Table 57. Zoetis Company Information
Table 58. Zoetis Introduction and Business Overview
Table 59. Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 60. Zoetis Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
Table 61. Zoetis Recent Development
Table 62. Boehringer Ingelheim Company Information
Table 63. Boehringer Ingelheim Introduction and Business Overview
Table 64. Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 65. Boehringer Ingelheim Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
Table 66. Boehringer Ingelheim Recent Development
Table 67. Jinhe Biotechnology Company Information
Table 68. Jinhe Biotechnology Introduction and Business Overview
Table 69. Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 70. Jinhe Biotechnology Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
Table 71. Jinhe Biotechnology Recent Development
Table 72. Merck Company Information
Table 73. Merck Introduction and Business Overview
Table 74. Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 75. Merck Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
Table 76. Merck Recent Development
Table 77. HIPRA Company Information
Table 78. HIPRA Introduction and Business Overview
Table 79. HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 80. HIPRA Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
Table 81. HIPRA Recent Development
Table 82. Ceva Santé Animale Company Information
Table 83. Ceva Santé Animale Introduction and Business Overview
Table 84. Ceva Santé Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 85. Ceva Santé Animale Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
Table 86. Ceva Santé Animale Recent Development
Table 87. Harbin Pharmaceutical Group Company Information
Table 88. Harbin Pharmaceutical Group Introduction and Business Overview
Table 89. Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 90. Harbin Pharmaceutical Group Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
Table 91. Harbin Pharmaceutical Group Recent Development
Table 92. Pulike Biotech Company Information
Table 93. Pulike Biotech Introduction and Business Overview
Table 94. Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 95. Pulike Biotech Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
Table 96. Pulike Biotech Recent Development
Table 97. Qilu Animal Health Products Company Information
Table 98. Qilu Animal Health Products Introduction and Business Overview
Table 99. Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 100. Qilu Animal Health Products Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
Table 101. Qilu Animal Health Products Recent Development
Table 102. Wuhan Keqian Biology Company Information
Table 103. Wuhan Keqian Biology Introduction and Business Overview
Table 104. Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 105. Wuhan Keqian Biology Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Offerings
Table 106. Wuhan Keqian Biology Recent Development
Table 107. Key Raw Materials Lists
Table 108. Raw Materials Key Suppliers Lists
Table 109. Inactivated Vaccine for Swine Mycoplasma Pneumonia Downstream Customers
Table 110. Inactivated Vaccine for Swine Mycoplasma Pneumonia Distributors List
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
List of Figures
Figure 1. Inactivated Vaccine for Swine Mycoplasma Pneumonia Product Picture
Figure 2. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value (2019-2030) & (US$ Million)
Figure 4. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume (2019-2030) & (K Units)
Figure 5. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Price (2019-2030) & (US$/Unit)
Figure 6. Inactivated Vaccine for Swine Mycoplasma Pneumonia Report Years Considered
Figure 7. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Players Revenue Ranking (2023) & (US$ Million)
Figure 8. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Players Sales Volume Ranking (2023) & (K Units)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Inactivated Vaccine for Swine Mycoplasma Pneumonia Revenue in 2023
Figure 10. Inactivated Vaccine for Swine Mycoplasma Pneumonia Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 11. Single Vaccine Picture
Figure 12. Dual Vaccine Picture
Figure 13. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 14. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value Market Share by Type, 2023 & 2030
Figure 15. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
Figure 16. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume Market Share by Type, 2023 & 2030
Figure 17. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price by Type (2019-2030) & (US$/Unit)
Figure 18. Product Picture of Piglets
Figure 19. Product Picture of Adult Pigs
Figure 20. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 21. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value Market Share by Application, 2023 & 2030
Figure 22. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
Figure 23. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume Market Share by Application, 2023 & 2030
Figure 24. Global Inactivated Vaccine for Swine Mycoplasma Pneumonia Price by Application (2019-2030) & (US$/Unit)
Figure 25. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value (2019-2030) & (US$ Million)
Figure 26. North America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Country (%), 2023 VS 2030
Figure 27. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value (2019-2030) & (US$ Million)
Figure 28. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Country (%), 2023 VS 2030
Figure 29. Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value (2019-2030) & (US$ Million)
Figure 30. Asia Pacific Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Country (%), 2023 VS 2030
Figure 31. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value (2019-2030) & (US$ Million)
Figure 32. South America Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Country (%), 2023 VS 2030
Figure 33. Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value (2019-2030) & (US$ Million)
Figure 34. Middle East & Africa Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Country (%), 2023 VS 2030
Figure 35. Key Countries/Regions Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value (%), (2019-2030)
Figure 36. Key Countries/Regions Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Volume (%), (2019-2030)
Figure 37. United States Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, (2019-2030) & (US$ Million)
Figure 38. United States Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Type (%), 2023 VS 2030
Figure 39. United States Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Application (%), 2023 VS 2030
Figure 40. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, (2019-2030) & (US$ Million)
Figure 41. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Type (%), 2023 VS 2030
Figure 42. Europe Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Application (%), 2023 VS 2030
Figure 43. China Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, (2019-2030) & (US$ Million)
Figure 44. China Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Type (%), 2023 VS 2030
Figure 45. China Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Application (%), 2023 VS 2030
Figure 46. Japan Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, (2019-2030) & (US$ Million)
Figure 47. Japan Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Type (%), 2023 VS 2030
Figure 48. Japan Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Application (%), 2023 VS 2030
Figure 49. South Korea Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, (2019-2030) & (US$ Million)
Figure 50. South Korea Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Type (%), 2023 VS 2030
Figure 51. South Korea Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Application (%), 2023 VS 2030
Figure 52. Southeast Asia Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, (2019-2030) & (US$ Million)
Figure 53. Southeast Asia Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Type (%), 2023 VS 2030
Figure 54. Southeast Asia Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Application (%), 2023 VS 2030
Figure 55. India Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value, (2019-2030) & (US$ Million)
Figure 56. India Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Type (%), 2023 VS 2030
Figure 57. India Inactivated Vaccine for Swine Mycoplasma Pneumonia Sales Value by Application (%), 2023 VS 2030
Figure 58. Inactivated Vaccine for Swine Mycoplasma Pneumonia Industrial Chain
Figure 59. Inactivated Vaccine for Swine Mycoplasma Pneumonia Manufacturing Cost Structure
Figure 60. Channels of Distribution (Direct Sales, and Distribution)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Smart Potentiometric Titrator - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Nov 05, 24
Multifunctional Zeta Potential Analyzer - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Nov 05, 24
Ultrapure Water pH Sensor - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Nov 05, 24
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232